Pig Xenotransplantation in Beta Cell Replacement: Addressing Challenges and Harnessing Potential for Type 1 Diabetes Therapy.

IF 2.7 3区 医学 Q1 SURGERY
Transplant International Pub Date : 2024-10-24 eCollection Date: 2024-01-01 DOI:10.3389/ti.2024.13122
Lorenzo Piemonti, Antonio Citro, Valentina Tomajer, Stefano Partelli, Rossana Caldara
{"title":"Pig Xenotransplantation in Beta Cell Replacement: Addressing Challenges and Harnessing Potential for Type 1 Diabetes Therapy.","authors":"Lorenzo Piemonti, Antonio Citro, Valentina Tomajer, Stefano Partelli, Rossana Caldara","doi":"10.3389/ti.2024.13122","DOIUrl":null,"url":null,"abstract":"<p><p>This opinion paper evaluates the potential of porcine islets as a promising alternative in beta cell replacement therapy for Type 1 Diabetes (T1D), juxtaposed with the current limitations of human donor islets. It analyzes the compatibility of pig islets with human glucose metabolism, their prospects as a limitless and high-quality source of beta cells, and the unique immunogenic challenges they present in xenotransplantation. Additionally, the paper discusses the regulatory and ethical considerations pertinent to the use of porcine islets. By synthesizing current research and expert perspectives, the paper highlights both the opportunities and significant barriers that need addressing to advance pig islets as a viable therapeutic option. The findings advocate for a balanced and forward-looking approach to the integration of pig islets in T1D treatment, underscoring the need for continued research and dialogue in this evolving field.</p>","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13122"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540633/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/ti.2024.13122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

This opinion paper evaluates the potential of porcine islets as a promising alternative in beta cell replacement therapy for Type 1 Diabetes (T1D), juxtaposed with the current limitations of human donor islets. It analyzes the compatibility of pig islets with human glucose metabolism, their prospects as a limitless and high-quality source of beta cells, and the unique immunogenic challenges they present in xenotransplantation. Additionally, the paper discusses the regulatory and ethical considerations pertinent to the use of porcine islets. By synthesizing current research and expert perspectives, the paper highlights both the opportunities and significant barriers that need addressing to advance pig islets as a viable therapeutic option. The findings advocate for a balanced and forward-looking approach to the integration of pig islets in T1D treatment, underscoring the need for continued research and dialogue in this evolving field.

猪异种移植在β细胞替代中的应用:应对挑战,挖掘 1 型糖尿病治疗潜力。
本意见书评估了猪胰岛作为 1 型糖尿病(T1D)β 细胞替代疗法的一种有前途的替代疗法的潜力,并将其与目前人类供体胰岛的局限性进行了对比。论文分析了猪胰岛与人类葡萄糖代谢的兼容性、猪胰岛作为无限的优质β细胞来源的前景,以及猪胰岛在异种移植中面临的独特免疫原性挑战。此外,本文还讨论了与使用猪胰岛有关的监管和伦理问题。通过综合当前的研究和专家观点,本文强调了将猪胰岛作为一种可行的治疗选择所面临的机遇和需要解决的重大障碍。研究结果主张采用平衡和前瞻性的方法将猪胰岛素用于治疗 T1D,强调了在这一不断发展的领域继续开展研究和对话的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transplant International
Transplant International 医学-外科
CiteScore
4.70
自引率
6.50%
发文量
211
审稿时长
3-8 weeks
期刊介绍: The aim of the journal is to serve as a forum for the exchange of scientific information in the form of original and high quality papers in the field of transplantation. Clinical and experimental studies, as well as editorials, letters to the editors, and, occasionally, reviews on the biology, physiology, and immunology of transplantation of tissues and organs, are published. Publishing time for the latter is approximately six months, provided major revisions are not needed. The journal is published in yearly volumes, each volume containing twelve issues. Papers submitted to the journal are subject to peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信